Business Wire

• cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of 90%1,2

• If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for cTTP

• Positive Opinion Based on Totality of Evidence, Including Results from the First Randomized, Controlled, Open-label, Crossover Phase 3 cTTP Trial

OSAKA, Japan & CAMBRIDGE,... (continue reading...)

MINNEAPOLIS--(BUSINESS WIRE)-- Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week. This convention, known for its global reach and influence, provides a... (continue reading...)

TACOMA, Wash.--(BUSINESS WIRE)-- TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, today announced that Chief Executive Officer Taryn Owen and Chief Financial Officer Carl Schweihs will be attending the Baird Global Consumer Technology & Services conference on Wednesday, June 5th and meeting with investors throughout the day.

About TrueBlue

TrueBlue (NYSE: TBI) is a leading provider of specialized workforce solutions that help clients... (continue reading...)

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has downgraded the Financial Strength Rating to B++ (Good) from A- (Excellent) and the Long-Term Issuer Credit Rating to “bbb” (Good) from “a-” (Excellent) of Louisiana Farm Bureau Mutual Insurance Company (Louisiana Farm Bureau) (Baton Rouge, LA). The outlook of these Credit Ratings (ratings) is negative.

The ratings reflect Louisiana Farm Bureau’s balance sheet strength, which AM Best assesses as strong, as well... (continue reading...)

xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoring

CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and... (continue reading...)